BioNTech and Bristol-Myers Squibb Detail Oncology Pipeline Assets
What happened
BioNTech SE will present new clinical information from its late-stage oncology pipeline at the European Society for Medical Oncology Congress in Madrid, Spain. The company detailed assets like pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, which is being jointly developed with Bristol-Myers Squibb. Additionally, pumitamig combined with elfetabart drozuntecan (elfe-D) is being jointly developed with Duality Biologics.
From investegate.co.uk
Why it matters
The presentations highlight BioNTech’s strategy to address unmet medical needs across various stages of disease. Prof. Özlem Türeci stated that the sixteen abstracts demonstrate momentum for the late-stage oncology pipeline across key assets and tumor areas.
From investegate.co.uk
Who's involved
- Bristol-Myers SquibbJointly developing pumitamig with BioNTech.
- Özlem TüreciPresented late-stage oncology pipeline data at ESMO.
- BioNTechPresenting new clinical information from its late-stage oncology pipeline.
- DUALITYJointly developing the B7-H3-targeting ADC elfe-D with BioNTech.
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Özlem Türeci
Turkish-German physician (born 1967)
Nothing else this week.
-
Mainz
capital of the federal state Rhineland-Palatinate, Germany
Nothing else this week.